Epidermolysis Bullosa Market Size to Exceed USD 9,913.2 Mn by 2032

The Epidermolysis Bullosa Market, estimated at USD 4,715.0 Mn in 2025, is expected to exhibit a CAGR of 11.2% and reach USD 9,913.2 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key players operating in the market are focusing on receiving product approvals from regulatory authorities and research and development activities, and this is expected to drive the market growth over the forecast period.

For instance, in October 2025, Abeona Therapeutics Inc. announced that the last patient has completed their 6-month follow-up visit in Abeona’s pivotal phase 3 VIITAL study of its investigational autologous, engineered cell therapy, EP-101, in patients with recessive dystrophic epidermolysis bullosa (RDEB).

Moreover, in September 2025, Relief Therapeutics Holding SA, a biopharmaceutical company announced that an investigator-initiated trial with Nexodyn for Epidermolysis Bullosa (EB) received Institutional Review Boards (IRB) approval.

Global Epidermolysis Bullosa Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) outbreak was first reported on December 31, 2025, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2025. According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 632,533,408 cases of coronavirus disease (COVID-19) were reported till November 8, 2025, across the globe.

Supply chain and manufacturing activities have been disrupted globally, due to lockdowns implemented by governments, restricted movement, and other COVID-19 safety precautions. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sectors which is majorly impacted by the COVID-19 pandemic.

Moreover, the coronavirus pandemic has had a negative impact on the development, production, and supply of pharmaceutical products used in the treatment of various diseases in North America, Europe, and Asia Pacific. The supply and production of pharmaceutical products are affected due to the imposition of lockdown during the COVID-19 pandemic. This lockdown has resulted in the closure of industrial establishments, except the manufacturing of essential commodities, and disruption in the supply chain of pharmaceutical products.

Browse 53 Market Data Tables and 38 Figures spread through 154 Pages and in-depth TOC on “Epidermolysis Bullosa Market” - Global Forecast to 2032, by Product Type (Antibiotic, Analgesics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Epidermolysis Bullosa Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/epidermolysis-bullosa-therapeutics-market-2214

Key players operating in the market are focusing on investments and product approvals. For instance, in December 2025, Fibrocell Science, Inc., a biotechnology company, announced that EB Research Partnership, Inc. and Epidermolysis Bullosa Medical Research Foundation (EBMRF) invested US$ 900,000 to help further the progress of FCX-007, the company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

Key Takeaways of the Epidermolysis Bullosa Market:

• The global epidermolysis bullosa market is expected to exhibit a CAGR of 11.2% over the forecast period, owing to rising launches and approvals of products. For instance, in October 2025, Castle Creek Biosciences, a biotechnology company, received an orphan product development grant from U.S. Food and Drug Administration (FDA) for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
• Among product type, antibiotics segment is expected to account for the largest market share during the forecast period, owing to rising research and development and product launches
• Key players operating in the global epidermolysis bullosa market include Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair